|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910830371803321 |
|
|
Autore |
Wiviott Stephen D. |
|
|
Titolo |
Antiplatelet therapy in ischemic heart disease / / Stephen D. Wiviott |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Hoboken, New Jersey : , : Wiley-Blackwell, , 2009 |
|
©2009 |
|
|
|
|
|
|
|
|
|
ISBN |
|
1-4443-0333-3 |
1-4443-0334-1 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (311 p.) |
|
|
|
|
|
|
Collana |
|
American Heart Association Clinical Series |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
|
|
Soggetti |
|
Coronary heart disease - Chemotherapy |
Blood platelets - Aggregation |
Coronary heart disease - drug therapy |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
|
|
|
|
|
Nota di contenuto |
|
Contents; Contributors; Preface; Foreword; PART I: Concepts in Platelet Physiology, Function, and Measurement; 1 Platelet physiology and the role of the platelet in ischemic heart disease; 2 Laboratory assessment of platelet function and the effects of antiplatelet agents; PART II: Pharmacology of Oral Antiplatelet Agents; 3 Cyclooxygenase inhibitors; 4 Aspirin response variability and resistance; 5 P2Y[sub(12)] inhibitors: Thienopyridines and direct oral inhibitors; 6 Thienopyridine response variability and resistance; PART III: Pharmacology of Intravenous Antiplatelet Agents |
7 Pharmacology of intravenous glycoprotein IIb/IIIa antagonists8 Intravenous P2Y[sub(12)] inhibitors; 9 Antiplatelet effects of thrombin inhibitors and fibrinolytic agents; PART IV: Clinical Use of Antiplatelet Agents in Cardiovascular Disease; 10 Antiplatelet therapy in acute coronary syndrome without ST elevation; 11 Antiplatelet therapy in ST-elevation myocardial infarction; 12 Antiplatelet therapy in chronic coronary artery disease; 13 Antiplatelet therapy in peripheral arterial disease; 14 Clinical use of antiplatelet agents in cardiovascular disease: cerebrovascular diseases |
PART V: Special Circumstances15 Antiplatelet therapy and coronary |
|
|
|
|